Summary:
To evaluate the efficacy of zilebesiran administered subcutaneously (SC) as an add-on therapy in patients with hypertension despite treatment with a standard of care antihypertensive medication.
You qualify if you have untreated hypertension (not taking antihypertensive medication), or
Treated hypertension on stable therapy with up to 2 antihypertensive medications.
Qualified Participants May Receive:
- $63.00 per completed visit
- You will be paid following each completed visit.